Cancer Biomarker Testing Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024
Cancer Biomarker Testing Market: Biomarker is any of body molecules that can be measured to assess the health. Molecules can be obtained from, body fluids, tissue or blood. Biomarker testing is also known as genetic testing or molecular testing.
(EMAILWIRE.COM, June 05, 2018 ) Cancer Biomarker Testing Market: Biomarker is any of body molecules that can be measured to assess the health. Molecules can be obtained from, body fluids, tissue or blood. Biomarker testing is also known as genetic testing or molecular testing. Biomarker test is a group of tests that look for these molecular signs of health so that doctors can plan best care. Cancer is referred as abnormal growth of the cells. Cancer biomarker is a process or substance that indicates the presence of cancer in the body. Genetic, epigenetic, glycemic, proteomic, and imaging biomarkers are used for cancer diagnosis, prognosis, and epidemiology. These cancer biomarkers used as risk indicators for various types of cancer such as lung cancer, breast cancer and prostate cancer among the others. Key cancer biomarkers include SCC, CEA, NSE Cyfra 21, PSA prostate cancer, TPA Lung cancer, CA153, EGF R, Cytokeratin 4 breast cancer and BRCA ½.
Cancer Biomarker Testing Market
The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization WHO stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2013. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market.
Cancer biomarker testing market segmented based on type of cancer, application, bio molecule and end user
Based on type of cancer, cancer biomarker test market is segmented into
Cervical cancer
Lung Cancer
Collateral Cancer
Liver Cancer
Prostate Cancer
Breast Cancer
Others
Get More Information about this Report @ https://www.planetmarketreports.com/reports/cancer-biomarker-testing-market-6096
Based on application, cancer biomarker test market is segmented into
Drug Discovery and Development
Personalised Medicine
Diagnosis
Others
Based on enduser, cancer biomarker test market is segmented into
Hospitals
Cancer diagnostic Centres
Research Institutes
Others
The global cancer biomarker test market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2018, Foundation Medicine and BristolMyers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient’s response to cancer immunotherapy. Using Foundation Medicine’s foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for BristolMyers Squibb BMS cancer drugs. For instance, in October 2017, Arquer Diagnostics Ltd. Arquer, and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer’s MCM5ELISA test in a wide range of cancers. In April 2017, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine RovaT, that helps to identify tumour cells.
Geographically cancer biomarker testing market segmented into following regions viz. North America, Europe, AsiaPacific, Latin America, and Middle East & Africa. North America is expected to be a major market for cancer biomarker test market owing to increase in research and development activities to diagnose and treating cancer and rise in prevalence of cancer. According to American Cancer Society ACS, in 2018, it estimates 1,688,780 new cancer cases are diagnosed and 600,920 cancer deaths in the U.S. alone. AsiaPacific region is expected to be fastest growing market due to increase in demand for the noninvasive techniques in diagnosis and prevention of cancer, high prevalence of cancer conditions in the region.
Some of the players in cancer biomarker test market are Thermo Fisher Scientific Affymetrix Inc. U.S., Abbott Laboratories U.S., F. HoffmannLa Roche Ltd. Switzerland, AbbVie Inc. U.S., Arquer Diagnostics Ltd. U.K., Illumina, Inc. U.S., Qiagen Germany, Agilent Technologies U.S., Merck & Co. Inc. U.S., Becton Dickinson and Company U.S., and Hologic Inc. U.S. to name a few.
In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urinebased testing
Table of Contents
Cancer Biomarker Market Report 2018
Executive Summary
2. Global Cancer Biomarker Market Introduction
3. Global Cancer Biomarker Market Dynamics
4. Global Cancer Biomarker Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
5. Global Cancer Biomarker Market, By Product Type, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
To be continuing….!!!
To Browse Similar Reports @ https://www.planetmarketreports.com/category/medical-devices
About Us :
Planet Market Reports gives statistical surveying reports to businesses, people and associations with a goal of helping them in their decision making process. We have huge database of market research reports & company profiles across globe. We associated with global market research a publisher who has a wide range of research specialists & industry experts which provides you deeper penetration of market research industry.
We have statistical surveying reports from number of top publishers and update our reports collections on daily basis with most recent research data to furnish our customers with the moment online access to our database. With access to this database, our customers will be able to benefit from expert insights on worldwide businesses, items, and market patterns. We help you in your buy choice by mapping your data needs with our immense accumulation of reports.
Contact Us :
Name: Ronald James
Email-Id: ronald.james@planetmarketreports.com
US : +1-716-2260907
UK : +447441952057
Organization: Planet Market Reports
Cancer Biomarker Testing Market
The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization WHO stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2013. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market.
Cancer biomarker testing market segmented based on type of cancer, application, bio molecule and end user
Based on type of cancer, cancer biomarker test market is segmented into
Cervical cancer
Lung Cancer
Collateral Cancer
Liver Cancer
Prostate Cancer
Breast Cancer
Others
Get More Information about this Report @ https://www.planetmarketreports.com/reports/cancer-biomarker-testing-market-6096
Based on application, cancer biomarker test market is segmented into
Drug Discovery and Development
Personalised Medicine
Diagnosis
Others
Based on enduser, cancer biomarker test market is segmented into
Hospitals
Cancer diagnostic Centres
Research Institutes
Others
The global cancer biomarker test market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2018, Foundation Medicine and BristolMyers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient’s response to cancer immunotherapy. Using Foundation Medicine’s foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for BristolMyers Squibb BMS cancer drugs. For instance, in October 2017, Arquer Diagnostics Ltd. Arquer, and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer’s MCM5ELISA test in a wide range of cancers. In April 2017, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine RovaT, that helps to identify tumour cells.
Geographically cancer biomarker testing market segmented into following regions viz. North America, Europe, AsiaPacific, Latin America, and Middle East & Africa. North America is expected to be a major market for cancer biomarker test market owing to increase in research and development activities to diagnose and treating cancer and rise in prevalence of cancer. According to American Cancer Society ACS, in 2018, it estimates 1,688,780 new cancer cases are diagnosed and 600,920 cancer deaths in the U.S. alone. AsiaPacific region is expected to be fastest growing market due to increase in demand for the noninvasive techniques in diagnosis and prevention of cancer, high prevalence of cancer conditions in the region.
Some of the players in cancer biomarker test market are Thermo Fisher Scientific Affymetrix Inc. U.S., Abbott Laboratories U.S., F. HoffmannLa Roche Ltd. Switzerland, AbbVie Inc. U.S., Arquer Diagnostics Ltd. U.K., Illumina, Inc. U.S., Qiagen Germany, Agilent Technologies U.S., Merck & Co. Inc. U.S., Becton Dickinson and Company U.S., and Hologic Inc. U.S. to name a few.
In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urinebased testing
Table of Contents
Cancer Biomarker Market Report 2018
Executive Summary
2. Global Cancer Biomarker Market Introduction
3. Global Cancer Biomarker Market Dynamics
4. Global Cancer Biomarker Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
5. Global Cancer Biomarker Market, By Product Type, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
To be continuing….!!!
To Browse Similar Reports @ https://www.planetmarketreports.com/category/medical-devices
About Us :
Planet Market Reports gives statistical surveying reports to businesses, people and associations with a goal of helping them in their decision making process. We have huge database of market research reports & company profiles across globe. We associated with global market research a publisher who has a wide range of research specialists & industry experts which provides you deeper penetration of market research industry.
We have statistical surveying reports from number of top publishers and update our reports collections on daily basis with most recent research data to furnish our customers with the moment online access to our database. With access to this database, our customers will be able to benefit from expert insights on worldwide businesses, items, and market patterns. We help you in your buy choice by mapping your data needs with our immense accumulation of reports.
Contact Us :
Name: Ronald James
Email-Id: ronald.james@planetmarketreports.com
US : +1-716-2260907
UK : +447441952057
Organization: Planet Market Reports
Contact Information:
Planet Market Reports
Himesh Khatri
Tel: 9834406269
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Planet Market Reports
Himesh Khatri
Tel: 9834406269
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results